Bayer: Debt Remains A Problem, Value Remains Compelling
Bayer Aktiengesellschaft remains undervalued despite a strong 18-month rally and ongoing operational improvements. I see upside potential supported by improving EBIT, robust pipeline assets, and technical breakout, though litigation and high debt persist. Litigation settlements and negative free cash flow weigh on the balance sheet, but recent Apollo investment and restructuring efforts provide some relief.
Apollo to Buy $3.4 Billion Stake in Bayer Contraceptives Business
The asset-management firm agreed to buy a minority stake in Bayer's long-acting reversible contraceptives business.
BAYRY Stock Surges 17% After Supreme Court Roundup Ruling
Bayer shares jump 17% after a Supreme Court ruling on Roundup litigation that could significantly reduce warning-based claims and litigation costs.
Bayer (BAYRY) Moves 17.0% Higher: Will This Strength Last?
Bayer (BAYRY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Bayer's stock jumps after Supreme Court sides with Roundup weedkiller manufacturer
The court ruled that states cannot have differing labeling warning rules than federal law requires.
Is Bayer (BAYRY) Outperforming Other Medical Stocks This Year?
Here is how Bayer Aktiengesellschaft (BAYRY) and Cardinal Health (CAH) have performed compared to their sector so far this year.
Bayer shares surge after U.S. Supreme Court rules in favour of company
Shares in Germany's Bayer surged by the most in 23 years on Thursday after the U.S. Supreme Court sided with the the company concerning lawsuits related its Roundup weedkiller.
Bayer Wins Supreme Court Challenge Over Roundup Litigation
The decision will help the company in its bid to resolve thousands of claims that the popular weedkiller caused cancer.
Bayer (BAYRY) Upgraded to Buy: What Does It Mean for the Stock?
Bayer (BAYRY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
EMA Begins Review of Bayer's Asundexian Filing for Stroke Prevention
BAYRY's asundexian enters EMA review for stroke prevention after phase III data showed a 26% cut in ischemic stroke without more major bleeding.
Bayer hopes to speed up biofuel feedstock plan amid Iran war energy crunch
Bayer is hoping to speed up a plan to facilitate North American production of biofuel feedstocks like camelina in the wake of the Iran war, the drug-making and crop science giant said on Wednesday.
BAYRY or RHHBY: Which Is the Better Value Stock Right Now?
Investors with an interest in Large Cap Pharmaceuticals stocks have likely encountered both Bayer Aktiengesellschaft (BAYRY) and Roche Holding AG (RHHBY). But which of these two stocks presents investors with the better value opportunity right now?
